Heart failure & cardiomyopathies
Development and Validation of a Prediction Model and Score for Transthyretin Cardiac Amyloidosis Diagnosis: T-Amylo
Authors' conclusion
The T-Amylo is a simple prediction model that improves the prediction of ATTR-CA diagnosis in patients with suspected ATTR-CA.
Study context
- Population
- Consecutive patients undergoing 99mTc-DPD scintigraphy for suspected although transthyretin cardiac amyloidosis (ATTR-CA)derivation 227
- Comparison
- T-Amylo prediction model vs Score
- Outcome
- ATTR-CA diagnosis (Grade 2 or 3 cardiac uptake on 99mTc-DPD scintigraphy without detectable monoclonal component, or amyloid on biopsy)
Methodological detailsretrospective, multicentre, external validation
- Retrospective
- Multicentre
- External validation
Performance
As reported in the abstract
Diagnostic accuracy for ATTR-CA
| Test or model | AUC (derivation) | AUC (validation) |
|---|---|---|
| T-Amylo prediction model | 0.92 | 0.84 |
| Score | 0.86 | 0.82 |
AUC (derivation)
T-Amylo prediction model0.92
Score0.86
AUC (validation)
T-Amylo prediction model0.84
Score0.82
Further findings
Accuracy in validation-cohort clinical scenarios: hypertensive cardiomyopathy (n = 327), severe AS (n = 105), HFpEF (n = 604)
- Good diagnostic accuracy in all 3 scenarios
Original publication
Development and Validation of a Prediction Model and Score for Transthyretin Cardiac Amyloidosis Diagnosis: T-Amylo. JACC Cardiovasc Imaging. Published 28 June 2023. doi:10.
Summarised from the published abstract; every number is checked against it